Avid Bioservices Inc (CDMO)

[cjgaddy]

Wxcbs, here are a couple of hints that they are…

7-14-09 CC:
CEO Steve King: “Fourth, we will continue our partnering efforts. We’ve had a significant uptick in interest in our Bavi oncology program and are continuing those discussions.”
SK/Q&A: “Partnering is an ongoing process, so we have many different programs which are available for licensing. That includes what we consider the big program, our Bavituximab cancer program, obviously Cotara, and then there are all of our preclinical dev. programs as well as our antiviral programs. So we take each one of these independently, and each one is in active discussions currently with potential partners. That process is that they have to obviously have an interest, generally provides them with non-confidential information, then confidential information under an appropriate agreement between the companies, and then they continue their due diligence process. We currently have everyone from major pharmaceutical companies to smaller companies interested in different technologies. On the Bavituximab cancer front, that’s everything from non-confidential packages to full due diligence that’s ongoing, so for us it’s a matter of finding the right partner. We obviously just don’t want any partner. We need to get value for the program that we feel like we’ve built into it and also value that we believe matches the potential of the program, and so got that program [Bavi-AC] we have some pretty high expectations. For preclinical programs, we have much more flexibility, and I think as we go forward, we should be able to bring some of these various programs’ partnering efforts to fruition. Since our current R&D efforts are really focused on the clinical developments, we’re actually in discussions with some of our preclinical programs. I think all of these go together to support what we’re trying to do as a company and to really realize some of the value that we’ve built into these different programs.”
http://tinyurl.com/nt4zql

6-3-09 PR: Peregrine highlights progress in all 3 Ph.2 Bavi Trials:
…CEO S.King, “Having just completed a busy round of successful data presentations and partnering meetings at ASCO’09, we are gratified at the level of interest the Bavi pgm is now receiving from leading cancer researchers & drug developers."
http://tinyurl.com/pe923n